Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Tango Therapeutics, Inc.

NASDAQ: TNGX · Life Sciences · 8 alerts · CIK 1819133

Share price
$24.17Close, Nov 16
Market cap
$4.1B
Shares outstanding
169.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tango Therapeutics, Inc. filings on SEC EDGAR ↗

6:39 PM ET Form 4
Insider Selling

Tango Therapeutics President, R&D Adam Crystal Sells $125K of Stock

Adam Crystal, President, R&D, sold 5,000 shares of Tango Therapeutics, Inc. at $25.00 a share, worth $125K in total on Nov 11, 2026. Shares held after the trade: 115,743 (-4.1%).

Value
$125K
Shares
5,000
Price
$25.00
Role
President, R&D
Holding change
-4.1%
Trade date
Nov 11, 2026
7:14 AM ET 8-K
Financial Results

Tango Therapeutics Financial Results

Tango Therapeutics reported third quarter 2026 financial results, highlighting a strong cash position of $977.5 million. The company announced plans to initiate a pivotal Phase 3 study of vopimetostat plus daraxonrasib for front-line pancreatic cancer in the first half of 2027 following positive Phase 1/2 data.

“In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer. This progress is rooted first in the data. Last month at ESMO, we shared promising data from the combination of vopimetostat plus daraxonrasib that reinforced the potential of this program to raise the bar for patients with MTAP-deleted and RAS-mutant pancreatic cancer.”

Malte Peters, MD, President and Chief Executive Officer of Tango
7:12 AM ET 10-Q
Financial Results

Tango Therapeutics Q3 2026 Results: Net Loss of $68.4M

Tango Therapeutics is a precision oncology company that remains in the clinical development stage with no approved products or revenue from sales. As of November 2, 2026, the company had 169,455,160 shares of common stock outstanding and continues to anticipate significant net losses as it advances its clinical programs, including a planned registrational trial for vopimetostat in 2027.

Key figure
Net loss $68.4M
7:35 PM ET Form 4
Insider Selling

Tango Therapeutics President, R&D Adam Crystal Sells $112K of Stock

Adam Crystal, President, R&D, sold 5,000 shares of Tango Therapeutics, Inc. at $22.26 to $22.99 a share (average $22.42) in 2 transactions, worth $112K in total on Nov 2, 2026. Shares held after the trade: 115,743 (-0.9%).

Value
$112K
Shares
5,000
Average price
$22.42
Role
President, R&D
Holding change
-0.9%
Trade date
Nov 2, 2026
7:32 PM ET Form 4
Insider Selling

Tango Therapeutics Principal Accounting Officer Jessica Newcomb Sells $158K of Stock

Jessica Newcomb, Principal Accounting Officer, sold 7,031 shares of Tango Therapeutics, Inc. at $22.28 to $22.98 a share (average $22.42) in 2 transactions, worth $158K in total on Nov 2, 2026. Shares held after the trade: 52,090 (-2.7%).

Value
$158K
Shares
7,031
Average price
$22.42
Role
Principal Accounting Officer
Holding change
-2.7%
Trade date
Nov 2, 2026
6:36 AM ET 8-K
Clinical Trial Data

Tango Therapeutics Clinical Trial Data

Tango Therapeutics announced updated Phase 1/2 clinical trial results for vopimetostat in combination with daraxonrasib, showing an 82% objective response rate in patients with MTAP-deleted and RAS-mutant pancreatic cancer. The data demonstrated a 9-month progression-free survival rate of 88%, leading the company to plan a registrational Phase 3 trial in the first half of 2027.

Counterparty
Revolution Medicines, Inc.
5:37 PM ET Form 4
Insider Selling

Tango Therapeutics President, R&D Adam Crystal Sells $661K of Stock

Adam Crystal, President, R&D, sold 27,000 shares of Tango Therapeutics, Inc. at $24.45 to $25.32 a share (average $24.47) in 2 transactions, worth $661K in total on Oct 1, 2026. Shares held after the trade: 115,743 (-0.5%).

Value
$661K
Shares
27,000
Average price
$24.47
Role
President, R&D
Holding change
-0.5%
Trade date
Oct 1, 2026
7:42 PM ET Form 4
Insider Selling

Tango Therapeutics Principal Accounting Officer Jessica Newcomb Sells $199K of Stock

Jessica Newcomb, Principal Accounting Officer, sold 8,200 shares of Tango Therapeutics, Inc. at $22.80 to $25.17 a share (average $24.22) in 3 transactions, worth $199K in total on Sep 22, 2026. Shares held after the trade: 59,121 (-3.9%).

Value
$199K
Shares
8,200
Average price
$24.22
Role
Principal Accounting Officer
Holding change
-3.9%
Trade date
Sep 22, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.